Eckert & Ziegler and Telix Partner to Support Phase III Prostate Cancer Study with Advanced Radiopharmaceutical Manufacturing

Eckert & Ziegler and Telix Partner to Support Phase III Prostate Cancer Study with Advanced Radiopharmaceutical Manufacturing

(IN BRIEF) Eckert & Ziegler has signed a multi-year agreement with Telix Pharmaceuticals to serve as the European contract manufacturing organization for Telix’s ProstACT GLOBAL Phase III study. The agreement includes supplying patients from Eckert & Ziegler’s Berlin facility and providing high-purity GMP-grade Lutetium-177. The partnership aims to advance Telix’s research on PSMA-positive prostate cancer, furthering both companies’ contributions to the radiopharmaceutical field.

(PRESS RELEASE) BERLIN, 14-Aug-2024 — /EuropaWire/ — Eckert & Ziegler and Telix Pharmaceuticals Limited (Telix) have announced a significant multi-year agreement in which Eckert & Ziegler will act as the European contract manufacturing organization (CMO) for Telix’s ProstACT GLOBAL Phase III study. Under this agreement, Eckert & Ziegler will supply all European patients involved in the study from their advanced manufacturing facility in Berlin. Additionally, the company will provide the essential starting material, high-purity, non-carrier added GMP-grade Lutetium-177 (Lu-177), crucial for the study.

Telix’s ProstACT GLOBAL study focuses on evaluating the benefits and risks of Lutetium (Lu 177) rosopatamab tetraxetan, a radio-labeled antibody drug conjugate (rADC), in adult men with prostate-specific membrane antigen (PSMA) positive prostate cancer, in combination with standard care treatments.

Dr. Harald Hasselmann, CEO of Eckert & Ziegler SE, expressed enthusiasm about the partnership: “We are pleased to expand our long-standing and successful collaboration with Telix. This contract highlights the significance of our state-of-the-art facility in Berlin and reinforces our position as a key service provider in the rapidly growing radiopharmaceutical market.”

Darren Patti, Group Chief Operating Officer of Telix, added: “Eckert & Ziegler’s exceptional expertise and the quality of their facilities were key factors in our decision to partner with them. We believe that this continued strategic partnership will play a significant role in the success of our ProstACT GLOBAL study.”

This collaboration marks a pivotal advancement in the ongoing efforts of both companies to drive innovation in the radiopharmaceutical sector. Eckert & Ziegler operates multiple CMO sites globally and provides a comprehensive range of services across the entire value chain.

About Eckert & Ziegler
Eckert & Ziegler SE, with more than 1,000 employees, is a leading specialist in isotope-related components for nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse. Contributing to saving lives.

Media Contact:

Robert-Rössle-Str. 10
13125 Berlin, Germany

Jan Schöpflin
Marketing
Karolin Riehle
Investor Relations
jan.schoepflin@ezag.de / karolin.riehle@ezag.de
Tel.: +49 (0) 30 / 94 10 84-138
www.ezag.com

SOURCE: Eckert & Ziegler SE